Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
Primary diagnosis | ||||||||
Date | 2008 | 2001 | 2002 | 2012 | 2004 | 2008 | 2005 | 2006 |
Initial PSA (ng/mL) | 40 | 6 | 24 | 26 | 29 | 7 | 72 | 14 |
Gleason score | 9 | 9 | 6 | 7a | 9 | 9 | 0 | 7b |
Metastases | LN | — | Bone | LN, bone | LN | — | LN | — |
Prior treatments | ||||||||
Primary therapy (RP/RT) | +/+ | +/+ | −/− | −/+ | +/+ | +/+ | +/+ | +/+ |
mCRPC therapies | ||||||||
Drugs | Docetaxel, abiraterone enzalutamide, 223Ra | Docetaxel* cabazitaxel, abiraterone, others† | Docetaxel, abiraterone enzalutamide, 223Ra | Docetaxel, abiraterone enzalutamide | Docetaxel*, abiraterone enzalutamide | Docetaxel, abiraterone enzalutamide | Docetaxel, abiraterone enzalutamide | Abiraterone enzalutamide |
Lines | 4 | 8 | 4 | 3 | 4 | 3 | 3 | 2 |
177Lu-PSMA-I&T | ||||||||
Initial treatment | ||||||||
Baseline PSA (ng/mL) | 605 | 97 | 1,193 | 227 | 176 | 950 | 63 | 124 |
Cycles | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 |
Posttherapy PSA (ng/mL) | <0.03 | 16 | 18 | 5 | 1 | 35 | 8 | 3 |
Maximum PSA response | −100% | −78% | −98% | −96% | −98% | −94% | −87% | −97% |
Free interval | ||||||||
Time (mo) | 14.7 | 5.1 | 3.8 | 6.7 | 4.9 | 4.9 | 6.9 | 5.7 |
Other therapies | ADT | ADT | ADT | ADT | ADT | ADT | ADT | ADT |
Rechallenge | ||||||||
Age (y) | 72 | 67 | 73 | 75 | 70 | 62 | 75 | 77 |
ECOG score | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
Sites of metastases | ||||||||
Bone | + | + | + | + | + | + | + | − |
Lymph node | + | + | − | + | − | + | + | + |
Viscera | − | Lung | − | Adrenal | − | − | − | − |
Baseline PSA (ng/mL) | 5 | 54 | 66 | 50 | 51 | 2,328 | 34 | 110 |
Cycles | 4 | 2 | 2 | 1 | 2 | 3 | 2 | 2 |
Maximum PSA response | −97% | 83% | −40% | −37% | −84% | −67% | 32% | −47% |
PSMA PET/CT response | PR | − | PR | PD | PR | PD | PD | PD |
Therapy discontinuation | Therapy break after excellent response | Tumor progress | Toxicity | Toxicity | Toxicity | Tumor progress | Tumor progress | Toxicity |
↵* Patients underwent initial docetaxel and docetaxel rechallenge.
↵† IGF-1R-antibody (NCT00313781), cabozantinib (COMET-1 Trial, NCT01605227).
LN = lymph node; RP = radical prostatectomy; RT = local radiotherapy; ADT = continuous androgen deprivation therapy; ECOG = Eastern Cooperative Oncology Group; PR = partial response; PD = progressive disease.